Scholarlink

<p>Targeted alpha therapy appears to be a promising approach in nuclear medicine for the treatment of cancers. Thanks to its appropriate physical properties, <sup>211</sup>At is an ideal candidate compared with other alpha emitters. Because of its enigmatic nature, the chemical element astatine is the subject of growing interest to better understand its radiochemistry. The application of <sup>211</sup>At in the clinic, which has shown good therapeutic results, is however still hampered. Stability issues of <sup>211</sup>At-radiolabeling were quickly encountered in early preclinical trials and later confirmed in the clinic that mainly studied <sup>211</sup>At-radiopharmaceuticals labeled by formation of an astatobenzamide derivative. Recent studies have shed light on the deastatination mechanisms encountered in vivo, in particular potential oxidative mechanisms that may weaken the carbon-astatine bond formed during the radiolabeling. In this work, we show that <i>ortho</i>-functionalization of astatoaryl compounds with benzyl alcohols protects radiolabeling from deastatination in a strongly oxidizing and acidic medium, as well as in liver microsomal media reproducing in vivo deastatination via cytochrome P450 (CYP450) mediated mechanisms. Our results open the way to the rational design of new <sup>211</sup>At-aryl-based compounds with improved stability.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Ortho-functionalization of a 211At-labeled aryl compound provides stabilization of the C-At bond against oxidative dehalogenation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月15日

查看全文
  • Romain Fouinneteau,
  • Clémence Maingueneau,
  • Nicolas Galland,
  • Cécile Perrio,
  • François Guérard

摘要

Targeted alpha therapy appears to be a promising approach in nuclear medicine for the treatment of cancers. Thanks to its appropriate physical properties, 211At is an ideal candidate compared with other alpha emitters. Because of its enigmatic nature, the chemical element astatine is the subject of growing interest to better understand its radiochemistry. The application of 211At in the clinic, which has shown good therapeutic results, is however still hampered. Stability issues of 211At-radiolabeling were quickly encountered in early preclinical trials and later confirmed in the clinic that mainly studied 211At-radiopharmaceuticals labeled by formation of an astatobenzamide derivative. Recent studies have shed light on the deastatination mechanisms encountered in vivo, in particular potential oxidative mechanisms that may weaken the carbon-astatine bond formed during the radiolabeling. In this work, we show that ortho-functionalization of astatoaryl compounds with benzyl alcohols protects radiolabeling from deastatination in a strongly oxidizing and acidic medium, as well as in liver microsomal media reproducing in vivo deastatination via cytochrome P450 (CYP450) mediated mechanisms. Our results open the way to the rational design of new 211At-aryl-based compounds with improved stability.